PAX3 expression was detected in 16 out of 34 tumour samples, regardless of subtype or translocation status, and it seems unlikely that a ‘dose’ effect of PAX3 activity may confer a transformed phenotype in RMS in which the PAX-FKHR fusion genes do not occur. The gene discussed is PAX3; the disease is neoplasm.